JP6505686B2 - 浸漬装置 - Google Patents
浸漬装置 Download PDFInfo
- Publication number
- JP6505686B2 JP6505686B2 JP2016526077A JP2016526077A JP6505686B2 JP 6505686 B2 JP6505686 B2 JP 6505686B2 JP 2016526077 A JP2016526077 A JP 2016526077A JP 2016526077 A JP2016526077 A JP 2016526077A JP 6505686 B2 JP6505686 B2 JP 6505686B2
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- unit
- volume
- immersion
- nitric oxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000007654 immersion Methods 0.000 title claims description 93
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 948
- 238000011282 treatment Methods 0.000 claims description 109
- 208000027418 Wounds and injury Diseases 0.000 claims description 62
- 206010052428 Wound Diseases 0.000 claims description 60
- 238000004519 manufacturing process Methods 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 38
- 239000002904 solvent Substances 0.000 claims description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 35
- 230000005855 radiation Effects 0.000 claims description 34
- 239000007864 aqueous solution Substances 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 28
- 230000001684 chronic effect Effects 0.000 claims description 23
- 230000010412 perfusion Effects 0.000 claims description 22
- 238000011049 filling Methods 0.000 claims description 21
- 239000003963 antioxidant agent Substances 0.000 claims description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims description 18
- 230000035876 healing Effects 0.000 claims description 17
- 208000002193 Pain Diseases 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 230000003078 antioxidant effect Effects 0.000 claims description 11
- 210000003141 lower extremity Anatomy 0.000 claims description 11
- 238000005086 pumping Methods 0.000 claims description 11
- 210000003414 extremity Anatomy 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 230000000004 hemodynamic effect Effects 0.000 claims description 8
- 230000009885 systemic effect Effects 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 230000004060 metabolic process Effects 0.000 claims description 7
- 238000001356 surgical procedure Methods 0.000 claims description 7
- 208000008960 Diabetic foot Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 230000004087 circulation Effects 0.000 claims description 6
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 206010012679 Diabetic neuropathic ulcer Diseases 0.000 claims description 4
- 201000009053 Neurodermatitis Diseases 0.000 claims description 4
- 208000030852 Parasitic disease Diseases 0.000 claims description 4
- 201000011152 Pemphigus Diseases 0.000 claims description 4
- 208000013544 Platelet disease Diseases 0.000 claims description 4
- 206010046996 Varicose vein Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 208000037976 chronic inflammation Diseases 0.000 claims description 4
- 230000006020 chronic inflammation Effects 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 230000007547 defect Effects 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 208000023589 ischemic disease Diseases 0.000 claims description 4
- 230000003902 lesion Effects 0.000 claims description 4
- 208000004296 neuralgia Diseases 0.000 claims description 4
- 208000021722 neuropathic pain Diseases 0.000 claims description 4
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 230000000638 stimulation Effects 0.000 claims description 4
- 208000027185 varicose disease Diseases 0.000 claims description 4
- 206010020852 Hypertonia Diseases 0.000 claims description 3
- 208000038016 acute inflammation Diseases 0.000 claims description 3
- 230000006022 acute inflammation Effects 0.000 claims description 3
- 239000012928 buffer substance Substances 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 239000002609 medium Substances 0.000 description 100
- 239000000243 solution Substances 0.000 description 92
- 239000000126 substance Substances 0.000 description 89
- 239000007789 gas Substances 0.000 description 51
- 239000002840 nitric oxide donor Substances 0.000 description 45
- 230000005670 electromagnetic radiation Effects 0.000 description 37
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 35
- 230000015572 biosynthetic process Effects 0.000 description 35
- 210000003491 skin Anatomy 0.000 description 28
- -1 nitric oxide radicals Chemical class 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 230000029663 wound healing Effects 0.000 description 19
- 239000000463 material Substances 0.000 description 18
- 235000006708 antioxidants Nutrition 0.000 description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 239000000872 buffer Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 239000011261 inert gas Substances 0.000 description 8
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 238000006303 photolysis reaction Methods 0.000 description 7
- 230000015843 photosynthesis, light reaction Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 239000001307 helium Substances 0.000 description 6
- 229910052734 helium Inorganic materials 0.000 description 6
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000003642 reactive oxygen metabolite Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- ICRHORQIUXBEPA-UHFFFAOYSA-N thionitrous acid Chemical compound SN=O ICRHORQIUXBEPA-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 208000005230 Leg Ulcer Diseases 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 150000001205 NO derivatives Chemical class 0.000 description 4
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000007975 buffered saline Substances 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- LZDSILRDTDCIQT-UHFFFAOYSA-N dinitrogen trioxide Chemical compound [O-][N+](=O)N=O LZDSILRDTDCIQT-UHFFFAOYSA-N 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 206010067171 Regurgitation Diseases 0.000 description 3
- 206010072170 Skin wound Diseases 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000003570 air Substances 0.000 description 3
- 239000012080 ambient air Substances 0.000 description 3
- 229940072107 ascorbate Drugs 0.000 description 3
- 238000010170 biological method Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229910001959 inorganic nitrate Inorganic materials 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 150000002832 nitroso derivatives Chemical class 0.000 description 3
- 230000036281 parasite infection Effects 0.000 description 3
- 238000000053 physical method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 239000012048 reactive intermediate Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011555 saturated liquid Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 108010081687 Glutamate-cysteine ligase Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 238000010891 electric arc Methods 0.000 description 2
- 239000007772 electrode material Substances 0.000 description 2
- 238000005868 electrolysis reaction Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 150000002826 nitrites Chemical class 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000007793 ph indicator Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- MUMXDRRTIYLYMY-YJKCNMNRSA-N (Z)-[dodecyl-[6-(dodecylazaniumyl)hexyl]amino]-oxido-oxidoiminoazanium Chemical compound CCCCCCCCCCCC[NH2+]CCCCCCN(CCCCCCCCCCCC)[N+](\[O-])=N\[O-] MUMXDRRTIYLYMY-YJKCNMNRSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- LUQZKEZPFQRRRK-UHFFFAOYSA-N 2-methyl-2-nitrosopropane Chemical class CC(C)(C)N=O LUQZKEZPFQRRRK-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 102000007989 Effector Caspases Human genes 0.000 description 1
- 108010089510 Effector Caspases Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100039696 Glutamate-cysteine ligase catalytic subunit Human genes 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 102100034294 Glutathione synthetase Human genes 0.000 description 1
- 101710101434 Glutathione synthetase Proteins 0.000 description 1
- 101710087514 Glutathione synthetase, chloroplastic Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 1
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 150000004008 N-nitroso compounds Chemical class 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 150000004009 O-nitroso compounds Chemical class 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108010001742 S-Nitrosoglutathione Proteins 0.000 description 1
- 150000004007 S-nitroso compounds Chemical class 0.000 description 1
- HYHSBSXUHZOYLX-WDSKDSINSA-N S-nitrosoglutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CSN=O)C(=O)NCC(O)=O HYHSBSXUHZOYLX-WDSKDSINSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013039 cover film Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000012052 hydrophilic carrier Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical class [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000018537 nitric oxide storage Effects 0.000 description 1
- 230000009935 nitrosation Effects 0.000 description 1
- 238000007034 nitrosation reaction Methods 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000001782 photodegradation Methods 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002037 poly(vinyl butyral) polymer Polymers 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000007845 reactive nitrogen species Substances 0.000 description 1
- 230000037309 reepithelialization Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000005361 soda-lime glass Substances 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 150000003610 tocomonoenols Chemical class 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/14—Devices for gas baths with ozone, hydrogen, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H35/00—Baths for specific parts of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H35/00—Baths for specific parts of the body
- A61H35/006—Baths for specific parts of the body for the feet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/30—Gas therapy for therapeutic treatment of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/04—Appliances for sand, mud, wax or foam baths; Appliances for metal baths, e.g. using metal salt solutions
- A61H2033/048—Baths using solutions, e.g. salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2230/00—Measuring physical parameters of the user
- A61H2230/25—Blood flowrate, e.g. by Doppler effect
- A61H2230/255—Blood flowrate, e.g. by Doppler effect used as a control parameter for the apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2230/00—Measuring physical parameters of the user
- A61H2230/50—Temperature
- A61H2230/505—Temperature used as a control parameter for the apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0266—Nitrogen (N)
- A61M2202/0275—Nitric oxide [NO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/12—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/08—Limbs
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rehabilitation Therapy (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Devices For Medical Bathing And Washing (AREA)
- Medicinal Preparation (AREA)
Description
b.対象物、特に躯幹の一部、四肢の一部または全身を浸漬するためのボリュームユニットであって、前記NO生成ユニットに連結され、前記キャリア媒体の役割をすると共に前記NO生成ユニットで生成されたNOで富化された浸漬媒体を保持することができるボリュームユニット。
・溶液を6.0〜7.4のpHの溶液に設定する緩衝塩
・50mM〜250mMのNOD
・50mM〜250mMの抗酸化剤
・pH6.0〜7.4のリン酸塩緩衝生理食塩水(PBS)
・100mMのNOD
・150mMの抗酸化剤
・8g/lのNaCl
・0.2g/lのKCl
・1.424g/lのNa2HPO4
・0.2g/lのKH2PO4
・8g/lのNaCl
・0.2g/lのKCl
・最終濃度50mM〜250mMの酢酸および酢酸ナトリウムの混合物
・溶液を5.0〜8.0のpHの溶液に設定する緩衝塩
・100mM〜250mMのNOD
・100mM〜250mMの抗酸化剤
・溶液を6.0〜7.4のpHの溶液に設定する緩衝塩
・50mM〜250mMのNOD
・50mM〜250mMの抗酸化剤
・pH6.0〜7.4のリン酸塩緩衝生理食塩水(PBS)
・100mMのNOD
・150mMの抗酸化剤
・8g/lのNaCl
・0.2g/lのKCl
・1.424g/lのNa2HPO4
・0.2g/lのKH2PO4
・8g/lのNaCl
・0.2g/lのKCl
・最終濃度50mM〜250mMの酢酸および酢酸ナトリウムの混合物
NO2 −+hν → N・+O・− (1)
O・−+H2O → OH・+OH− (2)
NO2 −+OH・ → NO2・+OH− (3)
NO2・+NO・ → N2O3 (4)
N2O3+H2O → 2NO2 −+2H+ (5)
NO2 −+hν → NO2・+e− aq (6)
e− aq+NO2 − → NO2 − (7)
NO2 −+H2O → NO・+2OH− (8)
NO・+NO2・ → N2O3 (9)
N2O3+H2O → 2NO2 −+2H+ (10)
N2O3+RS− → NO2 −+RSNO (11)
RSNO+hν → NO・+RS・ (12)
NO2・+RS− → NO2 −+RS・ (13)
NO・+RS → RSNO (14)
BA+OH・ → BA−OH (15)
VitC+NO2・ → NO2 −+VitC・− (16)
Trol+NO2・ → NO2 −+Trol・− (17)
NO2 −+H+ ⇔ HNO2 (18)
2HNO2 ⇔ N2O3+H2O (19)
N2O3 ⇔ NO・+NO2・ (20)
外用のために、NOは、ガスまたはNO含有プラズマの形態で、ならびに自然にまたは誘発により分解するNOドナーの形態で使用することができる。本発明は、溶媒中、例えば、浴溶液中に溶解される一酸化窒素ドナーを、物理化学的刺激を使って開裂させて、溶媒、例えば、浴溶液を生成された一酸化窒素で富化し、それにより、装置および浴溶液を使ってヒトおよび動物の医薬療法を強化し、ならびに種々の媒体をNOで富化することができる医用浴装置に関する。
−酸化還元状態(還元または酸化物質の存在)、
−温度、
−電流および/または電圧、
−周囲の圧力、
−電磁放射線の強度および浴溶液がNO生成ユニットにさらされている暴露期間、
−照射に暴露されている表面、
−NO放出剤への誘導量の作用期間、
−NO生成ユニットを通る浴溶液の流速、
−電磁放射線源と反応溶液との間の距離、
−電磁放射線源のスペクトル、
−浴溶液の吸収、伝達および反射特性、あるいは、
−最適NO放出に必要な「典型的な」物理化学的条件外であっても、触媒によりまたは適切な受容体特性により(例えば、UVAスペクトル外の電磁放射線であっても、NO形成薬剤からNOの放出を可能にできる発色団およびその他の物質によって)NO生成物質からの放出を可能とする、生物学的または化学的触媒またはメディエーターの濃度。
・糖尿病性足部病変および糖尿病性創傷の処置、
・糖尿病およびその他の疾病の場合の神経障害性疼痛の処置、
・静脈瘤の処置、
・組織の局所表在性疾患ならびに深部虚血疾患および血小板疾患の処置、
・皮膚の急性および慢性炎症、
・皮膚アレルギー、
・皮膚の寄生虫感染、
・アトピー性皮膚炎、特に神経皮膚炎、
・皮膚筋炎、
・尋常性天疱瘡および/またはその他の局所および全身性感染および/または急性および慢性炎症状態、
・創傷欠陥、例えば、慢性糖尿病性神経障害性潰瘍、
・下腿潰瘍、
・褥瘡創傷、
・二次癒合による感染創傷治癒、
・一次癒合による無刺激創傷治癒、特に切除裂傷または擦過創、
・(皮膚)移植、
・下肢(足または脚)の糖尿病性疼痛の処置、ならびに
・灌流不十分な皮弁形成手術の処置。
b)患者の躯幹の一部、四肢の一部または全身を浸漬装置のキャリア媒体中に浸漬すること。
・外科的創傷または事故関連創傷の処置;
・慢性創傷、非治癒性創傷または不十分な治癒創傷の処置;
・細菌感染創傷および/または真菌感染創傷の処置;
・炎症性疾患、免疫学的に調節された疾患または自己免疫疾患の範囲の皮膚科学的疾患の処置;
・糖尿病性足部病変および糖尿病性創傷の処置;
・神経障害性疼痛の処置;
・静脈瘤の処置;
・組織の局所表在性疾患ならびに深部虚血疾患および血小板疾患の処置;
・皮膚の急性および慢性炎症の処置;
・皮膚アレルギーの処置;
・皮膚の寄生虫感染の処置;
・アトピー性皮膚炎、特に神経皮膚炎、皮膚筋炎および尋常性天疱瘡の処置;
・慢性糖尿病性神経障害性潰瘍、下腿潰瘍、褥瘡創傷といった創傷欠陥の処置;
・全身性疾患、例えば、高血圧(筋緊張亢進)および関連する血流力学疾患の治療のための身体の広い領域の処置;
・(皮膚)移植の患者の処置;
・下肢(足または脚)の糖尿病性疼痛の処置、ならびに
・灌流不十分な皮弁形成手術の処置。
NO生成ユニットには、水道水、緩衝塩(8g/l NaCl+0.2g/l KCl+1.424g/l Na2HPO4+0.2g/l KH2PO4、pH=7.0)、1.45mMのNaNO2および10mMのアスコルビン酸ナトリウムを含めた。
この溶液を最初に安定性試験に供した。すなわち、20分間にわたりNOの含量がどのように変化するかを確かめた。2分毎に、10mLの一定分量の浴溶液をピペットによりフラスコ(容量175mL)に採取し、既に40mlのPBS溶液(pH7.4)を充填してあるフラスコにヘリウムガスを流した(100ml/分)。全手順中、フラスコから漏れ出たヘリウムガス混合物を直接NO分析ユニット(Eco Physics of Duernten、Switzerland製の化学発光検出器−CLD822Sr)に送った。この装置は、NO量を検出し、ガス混合物中のppm(百万分の一)含量で記録した(これに関しては、Oplaender et al.,2010(Nitric Oxide Biology & Chemistry,23:275−283)も参照されたい)。測定結果を図1Aに示す。NO含量は、約10%だけ低下したが、これは統計的に有意ではなく、20分間にわたり実質上一定であった。
上記の溶液を使って、上記のNO検出と並行して、NOの最も重要な酸化生成物として、上記測定を行っている間に、二酸化窒素ラジカルの量を検出した。この測定では、わずか10分後に1.5ppm以下の非常に低い濃度のNO2が発生し、その後20分間これらの濃度上昇は無視できる程度に過ぎなかった。しかし、測定されたNO2値は、初期値より有意に高い値ではなかった(図1B参照)。
ボランティア試験対象の片側の足を上記溶液(27℃)中に浸漬した。この溶液は、一定量のNOを含んでおり、この足浴中に合計10分間浸漬した。足浴の間、浸漬した足をわずかに動かすことにより、溶液を注意深く攪拌した。この10分間の暴露時間の間、さらには、その後の15分間にわたり、1mm〜2mmおよび6mm〜8mmの組織深さの位置の皮膚灌流に関して、足を分析した。また、紅斑の形成に関しても、足を検査した。
NO足浴中の10分間暴露後、両皮膚深さで、灌流の大きな増加が観察され(図2Aおよび2B)、その後、10〜15分の時間をかけて対照値のレベルまで戻った。また、一時的紅斑の形成に基づいて、増加した皮膚灌流を目視で観察することも可能であった(図3参照)。
Claims (9)
- a.UV照射源(6)およびNOD含有水溶液を保持するボリュームチャンバー(3)
を有する一酸化窒素(NO)生成ユニット(1)であり、前記水溶液がUV照射によるNOで富化されるように構成されているNO生成ユニット(1)と、
b.対象物を浸漬するためのボリュームユニット(2)であり、NOで富化されたと共に前記NO生成ユニット(1)から送られてきた前記水溶液を保持可能なボリュームユニット(2)と、を具備し、
前記ボリュームユニット(2)は、上端に向かって開いている容器であり、前記NO生成ユニット(1)は、堅く密閉可能である、浸漬装置であって、
前記水溶液は、共有壁中に配置された、前記NO生成ユニットと前記ボリュームユニットとを連結する2つの開口部を介して、または2つの配管を介して送られ、前記水溶液は、前記ボリュームチャンバー(3)および前記ボリュームユニット(2)が前記水溶液の閉回路を形成するように、循環機器またはポンプ圧送機器によって前記NO生成ユニット(1)のボリュームチャンバー(3)を通して送られ、また、前記ボリュームユニット(2)に戻されることが可能であり、
前記浸漬装置は、加熱または冷却によって、選択された温度に設定することを可能とする温度制御ユニットを備え、
前記UV照射源(6)は、適切な蛍光色素で被覆されたグロー放電ランプまたはガス放電ランプ(低圧放電または高圧放電)、発光ダイオード(LED)、有機発光ダイオード(OLED)、およびレーザーを含む群から選択される、
ことを特徴とする浸漬装置。 - 置換可能な充填容器を、前記NO生成ユニット(1)のボリュームチャンバー(3)および前記ボリュームユニット(2)の少なくとも一方に挿入することができ、前記充填容器は、NOD、緩衝物質、抗酸化剤および任意選択の溶媒を含む粉末状、ゲル状または液状の組成物を収納する、
ことを特徴とする請求項1に記載の浸漬装置。 - 前記置換可能な充填容器は、カートリッジである、
ことを特徴とする請求項2に記載の浸漬装置。 - 躯幹の一部、四肢の一部または全身をNOで富化された前記水溶液に浸漬することによる疾患の処置に使用するための、請求項1〜3のいずれか1項に記載の浸漬装置。
- 前記NO生成ユニット(1)は、前記処置の期間中、NO含量が増加または減少するように稼働される、
ことを特徴とする請求項4に記載の浸漬装置。 - 前記処置は、下記を含む群から選択されることを特徴とする請求項4または5に記載の浸漬装置:
a.外用によるヒトおよび動物の組織の代謝の刺激;
b.外科的創傷または事故関連創傷の処置;
c.慢性創傷、非治癒性創傷または不十分な治癒創傷の処置;
d.細菌感染創傷および真菌感染創傷の少なくとも一方の処置;
e.炎症性疾患、免疫学的に調節された疾患または自己免疫疾患の範囲の皮膚科学的疾患の処置;
f.糖尿病性足部病変および糖尿病性創傷の処置;
g.神経障害性疼痛の処置;
h.静脈瘤の処置;
i.組織の局所表在性疾患ならびに深部虚血疾患および血小板疾患の処置;
j.皮膚の急性および慢性炎症の処置;
k.皮膚アレルギーの処置;
l.皮膚の寄生虫感染の処置;
m.アトピー性皮膚炎、特に神経皮膚炎、皮膚筋炎および尋常性天疱瘡の処置;
n.慢性糖尿病性神経障害性潰瘍、下肢無痛潰瘍、褥瘡創傷といった創傷欠陥の処置;
o.全身性疾患、例えば、高血圧(筋緊張亢進)および関連する血流力学疾患の治療のための身体の広い領域の処置;
p.(皮膚)移植の患者の処置;
q.下肢(足または脚)の糖尿病性疼痛の処置、ならびに
r.不十分な灌流による皮弁形成手術の処置。 - 糖尿病患者の下肢の慢性創傷の処置に使用される、
ことを特徴とする請求項4または5に記載の浸漬装置。 - 前記処置は、数秒〜長時間継続することができる、
ことを特徴とする請求項4〜7のいずれか1項に記載の浸漬装置。 - 前記処置は、全身、躯幹の一部または四肢の一部をNOで富化された前記水溶液中に5〜30分間、好ましくは7.5〜20分間、特に好ましくは10〜15分間浸漬することを含む、
ことを特徴とする請求項8に記載の浸漬装置。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102013017524 | 2013-10-24 | ||
DE102013017524.0 | 2013-10-24 | ||
PCT/EP2014/072844 WO2015059273A1 (de) | 2013-10-24 | 2014-10-24 | Eintauchvorrichtung |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017505148A JP2017505148A (ja) | 2017-02-16 |
JP6505686B2 true JP6505686B2 (ja) | 2019-04-24 |
Family
ID=51870992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016526077A Active JP6505686B2 (ja) | 2013-10-24 | 2014-10-24 | 浸漬装置 |
Country Status (10)
Country | Link |
---|---|
US (1) | US10022527B2 (ja) |
EP (1) | EP3060189B1 (ja) |
JP (1) | JP6505686B2 (ja) |
CN (1) | CN105848624B (ja) |
AU (1) | AU2014338918B2 (ja) |
BR (1) | BR112016008928B1 (ja) |
CA (1) | CA2945724C (ja) |
MX (1) | MX371039B (ja) |
WO (1) | WO2015059273A1 (ja) |
ZA (1) | ZA201603353B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2528921A (en) * | 2014-08-05 | 2016-02-10 | Linde Ag | Plasma treatment of an infected nail or infected skin |
DE102016014942A1 (de) * | 2016-12-14 | 2018-06-14 | Lohmann & Rauscher Gmbh | Vorrichtung zur human- und tiermedizinischen Behandlung und Applikationseinrichtung dafür |
KR20210064346A (ko) * | 2018-09-27 | 2021-06-02 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | 가스 전달 디바이스들 |
AT17416U1 (de) | 2020-05-14 | 2022-03-15 | Rp Technik Gmbh | Beleuchtungsmittel, insbesondere zur Reduktion von Keimen, mit vorzugsweise wenigstens zwei Lichtquellen, sowie Verfahren zur Nutzung des Beleuchtungsmittels als mobiles Desinfektionsgerät |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5098415A (en) * | 1990-10-09 | 1992-03-24 | Jack Levin | Device and method for using an aqueous solution containing ozone to treat foot diseases |
US5396882A (en) | 1992-03-11 | 1995-03-14 | The General Hospital Corporation | Generation of nitric oxide from air for medical uses |
WO1995007610A1 (en) | 1993-09-13 | 1995-03-23 | Aga Aktiebolag | Method and means for generating nitric oxide |
JPH08126678A (ja) * | 1994-11-01 | 1996-05-21 | Hitachi Home Tec Ltd | 脚温浴器 |
JPH08252192A (ja) * | 1995-03-15 | 1996-10-01 | Toyo Tanso Kk | 風呂給湯装置 |
DK174312B1 (da) | 1996-06-06 | 2002-12-02 | Ole Pedersen | Fremgangsmåde til måling af strømningshastighed og diffusivitet, mikrosensor til brug ved fremgangsmåden samt anvendelse af sådan mikrosensor |
DE19823748C2 (de) | 1998-05-27 | 2000-05-18 | Siemens Ag | Verfahren und Vorrichtung zur plasmachemischen Erzeugung von Stickstoffmonoxid |
US7122018B2 (en) * | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
US6602212B1 (en) * | 2001-03-20 | 2003-08-05 | Shin-Young Ahn | Foot massage apparatus |
US6810288B2 (en) * | 2001-07-06 | 2004-10-26 | Ceramatec, Inc. | Device and method for wound healing and infection control |
US7122529B2 (en) | 2001-07-12 | 2006-10-17 | The Johns Hopkins University | Compounds that release nitric oxide at controlled rates upon photolysis |
US6673338B1 (en) | 2001-09-10 | 2004-01-06 | The United States Of America As Represented By The Department Of Health And Human Services | Nitric oxide-releasing imidate and thioimidate diazeniumdiolates, compositions, uses thereof and method of making same |
US20030039697A1 (en) | 2002-09-12 | 2003-02-27 | Yi-Ju Zhao | Matrices containing nitric oxide donors and reducing agents and their use |
US8017074B2 (en) * | 2004-01-07 | 2011-09-13 | Noxilizer, Inc. | Sterilization system and device |
US8663179B2 (en) * | 2004-03-22 | 2014-03-04 | Cure Care, Inc. | Wound treatment system and method of use |
US8708982B2 (en) * | 2005-05-04 | 2014-04-29 | Edward D. Lin | Wound protection and therapy system |
WO2007084533A2 (en) * | 2006-01-17 | 2007-07-26 | The University Of Akron | Debridement method using topical nitric oxide donor devices and compositions |
EP3023389B1 (de) | 2006-07-05 | 2020-03-18 | BSN medical GmbH | Vorrichtung zur photolytischen erzeugung von stickstoffmonoxid |
EP2051935B1 (en) | 2006-07-26 | 2016-09-07 | STMicroelectronics Srl | Use of nitroaniline derivatives for the production of nitric oxide |
US20120065576A1 (en) * | 2007-08-14 | 2012-03-15 | Stryker Corporation | Drug delivery system |
US8877508B2 (en) * | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
JP5071857B2 (ja) * | 2008-03-11 | 2012-11-14 | 学校法人東京理科大学 | 光触媒並びに硝酸イオンおよび亜硝酸イオン還元方法 |
CN101569781A (zh) * | 2008-04-30 | 2009-11-04 | 姚广权 | 一种治疗创口的装置 |
JP4543186B1 (ja) * | 2009-03-13 | 2010-09-15 | 国立大学法人茨城大学 | 二酸化窒素光分解コンバータおよび二酸化窒素光分解コンバータを備えた窒素酸化物濃度測定装置 |
US9084711B2 (en) * | 2009-11-24 | 2015-07-21 | Yukichika Kawakami | Human healing ability enhancing apparatus and method for actuating human healing ability enhancing apparatus |
JPWO2012086635A1 (ja) * | 2010-12-20 | 2014-05-22 | 中村 正一 | 心筋梗塞を予防、改善又は治療するための炭酸ガスミスト圧浴方法及び炭酸ガスミスト圧浴装置 |
-
2014
- 2014-10-24 CA CA2945724A patent/CA2945724C/en active Active
- 2014-10-24 AU AU2014338918A patent/AU2014338918B2/en active Active
- 2014-10-24 CN CN201480070296.2A patent/CN105848624B/zh active Active
- 2014-10-24 MX MX2016005064A patent/MX371039B/es active IP Right Grant
- 2014-10-24 BR BR112016008928-6A patent/BR112016008928B1/pt active IP Right Grant
- 2014-10-24 JP JP2016526077A patent/JP6505686B2/ja active Active
- 2014-10-24 US US15/030,865 patent/US10022527B2/en active Active
- 2014-10-24 EP EP14795974.6A patent/EP3060189B1/de active Active
- 2014-10-24 WO PCT/EP2014/072844 patent/WO2015059273A1/de active Application Filing
-
2016
- 2016-05-17 ZA ZA2016/03353A patent/ZA201603353B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2014338918A1 (en) | 2016-06-09 |
AU2014338918B2 (en) | 2019-09-12 |
EP3060189A1 (de) | 2016-08-31 |
BR112016008928A2 (ja) | 2017-08-01 |
BR112016008928B1 (pt) | 2022-04-19 |
CN105848624A (zh) | 2016-08-10 |
WO2015059273A1 (de) | 2015-04-30 |
CN105848624B (zh) | 2018-04-10 |
EP3060189B1 (de) | 2018-05-09 |
MX371039B (es) | 2020-01-13 |
CA2945724A1 (en) | 2015-04-30 |
US20160296738A1 (en) | 2016-10-13 |
MX2016005064A (es) | 2016-09-13 |
JP2017505148A (ja) | 2017-02-16 |
US10022527B2 (en) | 2018-07-17 |
ZA201603353B (en) | 2018-08-29 |
CA2945724C (en) | 2022-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016256577B2 (en) | Medical bathing device | |
JP6505686B2 (ja) | 浸漬装置 | |
Singh et al. | Photosensitized decomposition of S‐nitrosothiols and 2‐methyl‐2‐nitrosopropane Possible use for site‐directed nitric oxide production | |
US20150297782A1 (en) | Nitric oxide-releasing dressings | |
Hamblin | The role of nitric oxide in low level light therapy | |
JP6251348B2 (ja) | 一酸化窒素の生成方法及び装置 | |
US20040197274A1 (en) | Methods and apparatus for therapeutic treatment of respiratory, cardiac and other pathologies | |
JP2007532606A (ja) | 微生物の光力学的抑制のための調製物及び該調製物の使用 | |
RU2430756C1 (ru) | Способ уничтожения патогенных и условно-патогенных микроорганизмов | |
US20170354616A1 (en) | Onychomycosis treatment system and method | |
JP6942058B2 (ja) | No生成のための多段階プロセス | |
US20170354815A1 (en) | Onychomycosis treatment system and method | |
Vladimirov et al. | Molecular and cellular mechanisms triggered by low-level laser irradiation | |
Lubart et al. | Reactive oxygen species and photobiostimulation | |
KR20220104141A (ko) | 약물 수용 장치 및 관련 조성물 | |
US20180000937A1 (en) | Onychomycosis treatment system and method | |
WO2018175327A1 (en) | Onychomycosis treatment system and method | |
JP4819444B2 (ja) | 遺体の維持保存処理方法 | |
Chichuk et al. | Laser-induced priming of human blood leukocytes | |
JAKUBCZAK et al. | THE INFLUENCE OF LOW-POWER HELIUM-NEON LASER | |
Jasinski | Impact of Gaseous Nitric Oxide and Carbon Monoxide on Normal Excisional, Diabetic Excisional and Burn Wound Healing | |
CA2853013A1 (en) | Use of an albumin to stabilize chlorin e6 in aqueous solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20160621 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170921 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20171024 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171024 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20171225 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20171024 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180831 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181221 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190226 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190327 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6505686 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |